Mr. Hugh Rogers reports

TELO GENOMICS ANNOUNCES MANAGEMENT CHANGE

Kris Weinberg has stepped down as the chief executive officer (CEO) of Telo Genomics Corp. The company thanks Mr. Weinberg for his valuable contributions and wishes him the best in his future endeavours.

In connection with Mr. Weinberg's resignation, Telo Genomics is pleased to announce that it has appointed Dr. Sabine Mai as the company's interim CEO. Dr. Mai founded the company, created Telo Genomics' proprietary technology and has acted as a director of the company since 2016. Dr. Mai is the Canada Research Chair (Tier 1) in Genomic Instability and Nuclear Architecture of Cancer, as well as a professor of physiology and pathophysiology, biochemistry and medical genetics, human anatomy, and cell science at the University of Manitoba. Dr. Mai is also a director of The Genomic Centre for Cancer Research and Diagnosis (GCCRD) at the University of Manitoba.

In connection with Dr. Mai's appointment as interim CEO, the company has granted her 200,000 stock options to purchase up to 200,000 common shares of the company, pursuant to the company's 2022 stock option plan. The options are exercisable at 20 cents for a period of five years from the date of grant.

Dr. Mai remains a director and the chair of the clinical and scientific advisory board of Telo Genomics.

About Telo Genomics Corp.

Telo Genomics is a biotech company pioneering the most comprehensive telomere platform in the industry with powerful applications and prognostic solutions. These include liquid biopsies and related technologies in oncology and neurological diseases. Liquid biopsy is a rapidly growing field of significant interest to the medical community for being less invasive and more easily replicated than traditional diagnostic approaches. By combining the company's team's considerable expertise in quantitative analysis of 3-D telomeres with molecular biology and artificial intelligence to recognize disease associated genetic instability, Telo Genomics is developing simple and accurate products that improve day-to-day care for patients by serving the needs of pathologists, clinicians, academic researchers and drug developers. The benefits of the company's proprietary technology have been substantiated in over 150 peer-reviewed publications and in 25 clinical studies involving more than 3,000 patients with multiple cancers and Alzheimer's disease. The company's lead application, Telo-MM, is being developed to provide important, actionable information to medical professionals in the treatment of multiple myeloma, a deadly form of blood cancer.